Structural and Functional Mutations of the Perlecan Gene Cause Schwartz-Jampel Syndrome, with Myotonic Myopathy and Chondrodysplasia

• Published in: American journal of human genetics 2002-05, Vol.70 (5), p.1368-1375
• Main Authors: Arikawa-Hirasawa, Eri, Le, Alexander H., Nishino, Ichizo, Nonaka, Ikuya, Ho, Nicola C., Francomano, Clair A., Govindraj, Prasanthi, Hassell, John R., Devaney, Joseph M., Spranger, Jürgen, Stevenson, Roger E., Iannaccone, Susan, Dalakas, Marinos C., Yamada, Yoshihiko
• Format: Article
• Language: English
• Subjects: Base Sequence; Biological and medical sciences; Child; Child, Preschool; Diseases of striated muscles. Neuromuscular diseases; DNA Mutational Analysis; Exons - genetics; Genotype; Heparan Sulfate Proteoglycans - chemistry; Heparan Sulfate Proteoglycans - genetics; Heparan Sulfate Proteoglycans - metabolism; Humans; Infant; Male; Medical sciences; Mutation - genetics; Myotonic Disorders - complications; Myotonic Disorders - genetics; Myotonic Disorders - physiopathology; Neurology; Osteochondrodysplasias - complications; Osteochondrodysplasias - genetics; Osteochondrodysplasias - physiopathology; Phenotype; Structure-Activity Relationship
• ISSN: 0002-9297; 1537-6605
• DOI: 10.1086/340390

Perlecan, a large heparan sulfate proteoglycan, is a component of the basement membrane and other extracellular matrices and has been implicated in multiple biological functions. Mutations in the perlecan gene (HSPG2) cause two classes of skeletal disorders: the relatively mild Schwartz-Jampel syndrome (SJS) and severe neonatal lethal dyssegmental dysplasia, Silverman-Handmaker type (DDSH). SJS is an autosomal recessive skeletal dysplasia characterized by varying degrees of myotonia and chondrodysplasia, and patients with SJS survive. The molecular mechanism underlying the chondrodystrophic myotonia phenotype of SJS is unknown. In the present report, we identify five different mutations that resulted in various forms of perlecan in three unrelated patients with SJS. Heterozygous mutations in two patients with SJS either produced truncated perlecan that lacked domain V or significantly reduced levels of wild-type perlecan. The third patient had a homozygous 7-kb deletion that resulted in reduced amounts of nearly full-length perlecan. Unlike DDSH, the SJS mutations result in different forms of perlecan in reduced levels that are secreted to the extracellular matrix and are likely partially functional. These findings suggest that perlecan has an important role in neuromuscular function and cartilage formation, and they define the molecular basis involved in the difference in the phenotypic severity between DDSH and SJS.